BRAWNPharmaceuticals
Brawn Biotech Ltd — Profit & Loss Statement
₹20.85
-0.71%
Brawn Biotech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.00 | 0.00 | 0.30 | 0.22 | — |
| Normalized EBITDA | -1.68 Cr | -1.44 Cr | -0.30 Cr | -2.05 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Reconciled Depreciation | 0.11 Cr | 0.05 Cr | 0.11 Cr | 0.05 Cr | — |
| Reconciled Cost Of Revenue | 11.93 Cr | 14.36 Cr | 19.32 Cr | 6.61 Cr | — |
| EBITDA | -1.68 Cr | -1.44 Cr | -0.30 Cr | -2.05 Cr | — |
| EBIT | -1.79 Cr | -1.54 Cr | -0.40 Cr | -2.11 Cr | — |
| Net Interest Income | -37000.00 | -38000.00 | -60770.00 | -0.06 Cr | — |
| Interest Expense | 37000.00 | 38000.00 | 72950.00 | 0.01 Cr | — |
| Normalized Income | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Net Income From Continuing And Discontinued Operation | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Total Expenses | 15.35 Cr | 18.12 Cr | 21.09 Cr | 10.01 Cr | — |
| Diluted NI Availto Com Stockholders | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Net Income Common Stockholders | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Net Income Including Noncontrolling Interests | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Net Income Continuous Operations | -1.80 Cr | -1.54 Cr | -0.87 Cr | -1.64 Cr | — |
| Tax Provision | 0.00 | 0.00 | 0.46 Cr | -0.47 Cr | — |
| Pretax Income | -1.80 Cr | -1.54 Cr | -0.41 Cr | -2.12 Cr | — |
| Other Non Operating Income Expenses | 0.09 Cr | 0.09 Cr | 58790.00 | 15000.00 | — |
| Net Non Operating Interest Income Expense | -37000.00 | -38000.00 | -60770.00 | -0.06 Cr | — |
| Interest Expense Non Operating | 37000.00 | 38000.00 | 72950.00 | 0.01 Cr | — |
| Operating Income | -1.89 Cr | -1.63 Cr | -0.41 Cr | -2.06 Cr | — |
| Operating Expense | 3.42 Cr | 3.76 Cr | 1.77 Cr | 3.40 Cr | — |
| Other Operating Expenses | 2.18 Cr | 2.26 Cr | 0.96 Cr | 1.42 Cr | — |
| Depreciation And Amortization In Income Statement | 0.11 Cr | 0.10 Cr | 0.11 Cr | 0.05 Cr | — |
| Depreciation Income Statement | 0.11 Cr | 0.10 Cr | 0.11 Cr | 0.05 Cr | — |
| Gross Profit | 1.53 Cr | 2.13 Cr | 1.36 Cr | 1.34 Cr | — |
| Cost Of Revenue | 11.93 Cr | 14.36 Cr | 19.32 Cr | 6.61 Cr | — |
| Total Revenue | 13.46 Cr | 16.49 Cr | 20.67 Cr | 7.95 Cr | — |
| Operating Revenue | 13.46 Cr | 16.49 Cr | 20.67 Cr | 7.95 Cr | — |
| Total Unusual Items | — | -58300.00 | 0.00 | — | 0.00 |
| Total Unusual Items Excluding Goodwill | — | -58300.00 | 0.00 | — | 0.00 |
| Interest Income | — | 0.09 Cr | 33550.00 | 0.00 | 43960.00 |
| Rent Expense Supplemental | — | 0.48 Cr | 0.47 Cr | 0.38 Cr | 0.30 Cr |
| Diluted Average Shares | — | 0.30 Cr | 0.30 Cr | 0.30 Cr | 0.30 Cr |
| Basic Average Shares | — | 0.30 Cr | 0.30 Cr | 0.30 Cr | 0.30 Cr |
| Diluted EPS | — | -5.14 | -2.89 | -5.48 | -1.84 |
| Basic EPS | — | -5.14 | -2.89 | -5.48 | -1.84 |
| Special Income Charges | — | -58300.00 | 0.00 | — | 0.00 |
| Other Special Charges | — | 58300.00 | — | — | — |
| Total Other Finance Cost | — | 9610.00 | 21370.00 | 0.05 Cr | 0.02 Cr |
| Interest Income Non Operating | — | 0.09 Cr | 33550.00 | 0.00 | 43960.00 |
| Selling General And Administration | — | 0.30 Cr | 0.38 Cr | 0.41 Cr | 0.35 Cr |
| Selling And Marketing Expense | — | 0.20 Cr | 0.19 Cr | 0.18 Cr | 0.12 Cr |
| General And Administrative Expense | — | 0.10 Cr | 0.19 Cr | 0.23 Cr | 0.23 Cr |
| Rent And Landing Fees | — | 0.48 Cr | 0.47 Cr | 0.38 Cr | 0.30 Cr |
| Net Income Discontinuous Operations | — | — | — | 0.00 | 0.00 |
| Write Off | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Brawn Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.